We examined the association between IL28B single-nucleotide-polymorphism rs12979860, hepatitis C virus (HCV) kinetic and pegylated-interferon-alpha-2a pharmacodynamic parameters in HIV/HCV-co-infected patients from South America.
Introduction
Coinfection with human immunodeficiency virus (HIV) and HCV affects approximately 10 million people worldwide 1 and up to 100,000 persons in Brazil
2
. Antiviral therapy for hepatitis C virus (HCV) consisting of pegylated-interferon- (PEG-IFN) and ribavirin (standard of care, SOC) has potential adverse effects, and response rates are lower in HCV/HIV co-infected than in HCV-monoinfected patients [3] [4] [5] [6] [7] [8] [9] . Consequently, there is considerable interest in identifying better predictors of treatment response. A seminal study showed that single nucleotide polymorphisms (SNPs) in the IL28B gene region were associated with race/ethnicity and correlated with response to pegylated interferon-alpha (PEG-IFN) and ribavirin therapy in HCV mono-infected patients [10] [11] [12] [13] .
Recently, early HCV kinetics (e.g., first and second phases of viral decline) have been evaluated as a function of IL28B SNPs in HCV mono-infected patients, although pharmacodynamic parameters are lacking in these analyses 14, 15 . To the best of our knowledge, there is no such information in HIV/HCV co-infected individuals. To determine the relationship between IL28B polymorphisms and viral/host parameters in HIV/HCV co-infected patients, we compared IL28B genotypes with recent results of viral response 16 and estimates of viral kinetic and pharmacodynamic parameters 17 in 26 patients with HIV and HCV who were treated with PEG-IFN--2a and ribavirin. 
Patients and Methods
Data form twenty six HIV/HCV co-infected patients who were treated with PEG-IFN2a (180 μg/week) plus weight based ribavirin (11 mg/kg/day) and provided informed written consent for DNA and HCV RNA kinetic testing are included here. Detailed baseline characteristics, viral response and viral kinetic and pharmacodynamic parameters, estimated via mathematical modeling, were recently studied 16, 17 . The SNP near the IL28B gene, rs12979860, was examined using the 5' nuclease assay with allele specific PCR probes as recently described
10
. 
Results
Baseline characteristics and IL28B polymorphism. There were no differences in the distribution of IL28B genotypes by age, gender or race/ethnicity (Table S1 ). Notably, patients by week 12 of therapy (Table S1 ). The response rates among HCV genotype (1 vs 3) and IL28B genotype (CC vs CT/TT) are shown in Table S1 .
Viral kinetics and IL28B polymorphism. Overall, the first phase viral decline from baseline to nadir viral load (see V min in Table 1 ) was significantly (p=0.005) higher in patients with genotype-CC (median (IQR) 1.7 (0.6)) than in patients with genotype-TC/TT (0.92 (0.8), Table 1 and Fig. 1A ). The slower-second-phase slopes calculated from day 7 to day 15 or from day 2 to day 29 also were significantly faster (p=0.046 and p=0.01, respectively) in patients with genotype-CC (median (IQR) 1.1 (1.1) and 0.7(0.6) log/wk, respectively) than in patients with genotype-TC/TT (0.4(0.5) and 0.3(0.4) log/wk, respectively, raises the possibility that the IL28B genotype mediates endogenous production of IFN-, which contributes to the first phase response by stimulating IFN signaling.
The second phase viral decline slope also was associated with genotype-CC in genotype 1 patients (Table 1 ). The overall correlation between the CC-genotype and the infection death/loss rate,  was less prominent (trend, p=0.11). This discrepancy could be explained by the fact that 6 out of 21 of patients who finished 48 weeks of therapy in our study 17 had a triphasic viral decline pattern, consisting of a first phase
(1-2 days) with a rapid virus load decline followed by a "shoulder phase" (8 -28 days), in which virus levels decay slowly or remain constant, and a third phase of renewed viral decay 20, 21 . Calculating the slower phase slope from the measured data includes the "shoulder phase" in these triphasic patients. In contrast, by using a mathematical model that includes hepatocytes proliferation, estimated  reflects the final slope and excludes the shoulder phase
22
. Interestingly, five of the six triphasic patients had genotype-TT/TC and only one had genotype-CC (not shown). In addition, we recently showed that drug effectiveness, , can significantly affect the serum second phase slope decline
, and that when  ~ 1 the slower phase slope is close to . Indeed, when . Thus, although the slower phase slope, and as a consequence RVR rates, are correlated with the IL28B genotype, the driving effect is the difference in the IFN antiviral effectiveness in blocking virion production (first phase decline). The data suggest that the IL28B polymorphism has less of an effect on the infected-cell-loss rate that has been attributed to immune mediated clearance of infected cells
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.
Among viral response parameters, we found that RVR and cEVR rates are significantly associated with genotype-CC (Table S1 ), in agreement with recent results in HCV (genotypes 1/2/3) monoinfected patients 15, 24 . Among HCV genotype-1 subjects in our study, 10 subjects (out of 11) who had genotype CT/TT failed to achieve an SVR in agreement with the strong association recently shown in larger HIV/HCV co-infected cohorts by Rallon et al. 25 and Pineda et al 26 . However, the weak association between genotype-CC and SVR (p=0.3; Table S1 ) in HCV genotype-1 infected subjects in our study may be related to the small sample size and due the discontinuation of five patients at week 12 of therapy as previously explained 17 . The faster first and second phase viral declines observed in IL28B genotype-1-CC patients and the higher first phase viral decline in genotype-3-CC patients provide evidence that the IL28B genotype favorably impacts on viral kinetics.
Evaluation of baseline characteristics showed genotype-CC subjects had a higher body weight. Larger studies are needed to evaluate whether genotype CC might overcome the deleterious impact of higher body weight on SVR. In addition, there was
a significantly higher proportion of IL28B genotype-CC in patients infected with HCVgenotype 3 than in patients infected with HCV-genotype 1 (Table S1) . We previously reported higher first and faster second phase viral declines in genotype-3 compared to genotype-1 HIV/HCV co-infected patients 16 . In the current study, we identified a higher prevalence of IL28B CC-genotype in HCV genotype-3
cases, but no association between IL28B genotype and the second phase viral decline or the loss rate of HCV-infected cells, . Since the second-slope phase and/or  correlate with the outcome of therapy
, these findings suggest that the relatively rapid second phase viral decline in genotype-3 patients is related to factors other than the genetic polymorphism. Our observations might explain the lack of association between IL28B genotype and SVR in genotype-3 patients recently reported by Rallon et al. 25 In contrast, higher  7average and  were associated (trend, p=0.1) with CCgenotype in HCV genotype-1 infected patients. The trends observed in genotype-1 patients may reflect the small sample size and is anticipated to be significant in larger studies.
Previous studies of HCV mono-infected patients conducted in the United States reported a higher proportion of IL28B genotype-TC/TT in African Americans than in non-Hispanic Caucasians 10, 14 . In contrast, we did not identify a significant (p=0.5) difference in IL28B genotype frequencies between African Americans and White patients from Brazil (Table 1) . The lack of an association between race and IL28B genotype in our South American patient population might partly explain the lack of association between race/ethnicity and viral kinetic parameters or viral response patterns in our recent reports 16, 17 . Indeed, preliminary results indicate that ~8 0% ( and (F) viral kinetics from initiation of therapy until week 12, in patients infected with HCV genotype-1/3 (GT-1/3), genotype-1 (GT-1) or genotype-3 (GT-3), respectively.
Statistical differences in the first and slower (second) phases of viral decline are shown in Table 1 . Gray filled symbols represent undetectable HCV RNA (<10 IU/ml) in all patients at week 12. Vertical lines represent standard error of the mean (note that in (E) and (F) vertical lines in genotype-TC curve (circles) are missing since the curve represents one patient). 
